- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/54 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 233/54
Total number of patents in this class: 349
10-year publication summary
|
16
|
17
|
25
|
16
|
18
|
8
|
14
|
6
|
13
|
5
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Alnylam Pharmaceuticals, Inc. | 1150 |
17 |
| Janssen Pharmaceutica N.V. | 3413 |
9 |
| Bristol-myers Squibb Company | 4875 |
8 |
| BASF SE | 20803 |
8 |
| Merck Patent GmbH | 5850 |
7 |
| Probiodrug AG | 63 |
7 |
| Novartis AG | 10883 |
6 |
| Universal Display Corporation | 1885 |
6 |
| Theravance Biopharma R&D IP, LLC | 461 |
6 |
| F. Hoffmann-La Roche AG | 7923 |
5 |
| Chevron Phillips Chemical Company LP | 1835 |
4 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 692 |
4 |
| Eastman Chemical Company | 2207 |
4 |
| AstraZeneca AB | 2933 |
3 |
| Boehringer Ingelheim International GmbH | 4698 |
3 |
| FUJIFILM Corporation | 29251 |
3 |
| The General Hospital Corporation | 4710 |
3 |
| BioCryst Pharmaceuticals, Inc. | 177 |
3 |
| Eli Lilly and Company | 3825 |
3 |
| Exelixis, Inc. | 406 |
3 |
| Other owners | 237 |